{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T10:30:33Z","timestamp":1789122633728,"version":"build-2803163510"},"reference-count":29,"publisher":"Elsevier BV","issue":"2-3","license":[{"start":{"date-parts":[[2009,5,1]],"date-time":"2009-05-01T00:00:00Z","timestamp":1241136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,5,1]],"date-time":"2009-05-01T00:00:00Z","timestamp":1241136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Chemico-Biological Interactions"],"published-print":{"date-parts":[[2009,5]]},"DOI":"10.1016\/j.cbi.2008.10.008","type":"journal-article","created":{"date-parts":[[2008,10,18]],"date-time":"2008-10-18T04:18:34Z","timestamp":1224303514000},"page":"233-239","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Comparison of pharmacokinetic and pharmacodynamic profiles of aspirin following oral gavage and diet dosing in rats"],"prefix":"10.1016","volume":"179","author":[{"given":"Izet M.","family":"Kapetanovic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth S.","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel M.","family":"Tessier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew O.","family":"Lindeblad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander D.","family":"Zakharov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Lubet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Lyubimov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.cbi.2008.10.008_bib1","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s11883-007-0053-0","article-title":"Aspirin in the treatment and prevention of cardiovascular disease: current perspectives and future directions","volume":"9","author":"Hennekens","year":"2007","journal-title":"Curr. Atheroscler. Rep."},{"issue":"3","key":"10.1016\/j.cbi.2008.10.008_bib2","doi-asserted-by":"crossref","first-page":"s25","DOI":"10.1161\/ATVBAHA.107.160481","article-title":"Aspirin: promise and resistance in the new millennium","volume":"28","author":"Patrono","year":"2008","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"10","key":"10.1016\/j.cbi.2008.10.008_bib3","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1056\/NEJMoa021735","article-title":"A randomized trial of aspirin to prevent colorectal adenomas","volume":"348","author":"Baron","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cbi.2008.10.008_bib4","doi-asserted-by":"crossref","first-page":"493","DOI":"10.2174\/1568026054201631","article-title":"Low dose aspirin, COX-inhibition and chemoprevention of colorectal cancer","volume":"5","author":"Benamouzig","year":"2005","journal-title":"Curr. Top. Med. Chem."},{"issue":"4","key":"10.1016\/j.cbi.2008.10.008_bib5","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1093\/jnci\/94.4.252","article-title":"Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues","volume":"94","author":"Thun","year":"2002","journal-title":"J. Natl. Cancer Inst."},{"issue":"2","key":"10.1016\/j.cbi.2008.10.008_bib6","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1097\/01.cej.0000197451.02604.25","article-title":"Non-steroidal anti-inflammatory drug use and prostate cancer in a high-risk population","volume":"15","author":"Mahmud","year":"2006","journal-title":"Eur. J. Cancer Prev."},{"issue":"8","key":"10.1016\/j.cbi.2008.10.008_bib7","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1093\/jnci\/djk132","article-title":"A large cohort study of long-term daily use of adult-strength aspirin and cancer incidence","volume":"99","author":"Jacobs","year":"2007","journal-title":"J. Natl. Cancer Inst."},{"issue":"12","key":"10.1016\/j.cbi.2008.10.008_bib8","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1002\/cncr.21075","article-title":"Nuclear factor kappa B activation is a potential target for preventing pancreatic carcinoma by aspirin","volume":"103","author":"Sclabas","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.cbi.2008.10.008_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-4615-1657-6_1","article-title":"Agent identification and preclinical testing","volume":"106","author":"Crowell","year":"2001","journal-title":"Cancer Treat. Res."},{"issue":"1\u20132","key":"10.1016\/j.cbi.2008.10.008_bib10","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.cbi.2006.08.019","article-title":"Effects of oral dosing paradigms (gavage versus diet) on pharmacokinetics and pharmacodynamics","volume":"164","author":"Kapetanovic","year":"2006","journal-title":"Chemico-biol. Interact."},{"issue":"3","key":"10.1016\/j.cbi.2008.10.008_bib11","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1093\/carcin\/20.3.425","article-title":"Prevention by aspirin and its combination with alpha-difluoromethylornithine of azoxymethane-induced tumors, aberrant crypt foci and prostaglandin E2 levels in rat colon","volume":"20","author":"Li","year":"1999","journal-title":"Carcinogenesis"},{"issue":"8","key":"10.1016\/j.cbi.2008.10.008_bib12","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1093\/carcin\/14.8.1493","article-title":"Inhibitory effect of aspirin on azoxymethane-induced colon carcinogenesis in F344 rats","volume":"14","author":"Reddy","year":"1993","journal-title":"Carcinogenesis"},{"issue":"5\u20136","key":"10.1016\/j.cbi.2008.10.008_bib13","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0049-3848(03)00379-7","article-title":"The mechanism of action of aspirin","volume":"110","author":"Vane","year":"2003","journal-title":"Thrombosis Res."},{"issue":"3","key":"10.1016\/j.cbi.2008.10.008_bib14","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/BF01062139","article-title":"Testing for the equality of area under the curves when using destructive measurement techniques","volume":"16","author":"Bailer","year":"1988","journal-title":"J. Pharm. Biopharm."},{"issue":"3","key":"10.1016\/j.cbi.2008.10.008_bib15","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/S0022-3565(25)24107-6","article-title":"Nonlinear pharmacokinetics of aspirin in rats","volume":"245","author":"Wientjes","year":"1988","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"6","key":"10.1016\/j.cbi.2008.10.008_bib16","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.bcp.2005.06.011","article-title":"Salicylic acid modulates oxidative stress and glutathione peroxidase activity in the rat colon","volume":"70","author":"Drew","year":"2005","journal-title":"Biochem. Pharmacol."},{"issue":"2","key":"10.1016\/j.cbi.2008.10.008_bib17","first-page":"503","article-title":"Sodium salicylate induces apoptosis in HCT116 colorectal cancer cells through activation of p38MAPK","volume":"23","author":"Lee","year":"2003","journal-title":"Int. J. Oncol."},{"issue":"2","key":"10.1016\/j.cbi.2008.10.008_bib18","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.plefa.2004.11.001","article-title":"Control of cyclooxygenase-2 transcriptional activation by pro-inflammatory mediators","volume":"72","author":"Wu","year":"2005","journal-title":"Prostaglandins Leukot. Essent. Fatty Acids"},{"issue":"1","key":"10.1016\/j.cbi.2008.10.008_bib19","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1006\/jsre.1998.5560","article-title":"Salicylates inhibit NF-kappaB activation and enhance TNF-alpha-induced apoptosis in human pancreatic cancer cells","volume":"83","author":"McDade","year":"1999","journal-title":"J. Surg. Res."},{"issue":"1","key":"10.1016\/j.cbi.2008.10.008_bib20","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/S1091-255X(00)80029-3","article-title":"Sodium salicylate inhibits proliferation and induces G1 cell cycle arrest in human pancreatic cancer cell lines","volume":"4","author":"Perugini","year":"2000","journal-title":"J. Gastrointest. Surg."},{"issue":"2","key":"10.1016\/j.cbi.2008.10.008_bib21","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1006\/jsre.1999.5630","article-title":"Sodium salicylate inhibits macrophage TNF-alpha production and alters MAPK activation","volume":"84","author":"Vittimberga","year":"1999","journal-title":"J. Surg. Res."},{"issue":"13","key":"10.1016\/j.cbi.2008.10.008_bib22","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1001\/archinte.162.13.1531","article-title":"Endogenous salicylates, aspirin, and inflammation","volume":"162","author":"Paterson","year":"2002","journal-title":"Arch. Intern. Med."},{"issue":"49","key":"10.1016\/j.cbi.2008.10.008_bib23","doi-asserted-by":"crossref","first-page":"38261","DOI":"10.1074\/jbc.M005545200","article-title":"Salicylate-induced growth arrest is associated with inhibition of p70s6k and down-regulation of c-myc, cyclin D1, cyclin A, and proliferating cell nuclear antigen","volume":"275","author":"Law","year":"2000","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.cbi.2008.10.008_bib24","first-page":"697","article-title":"Salicylate inhibition of rat mammary carcinogenesis and angiogenesis in female rat compatible with misoprostol administration","volume":"26","author":"Ghezzo","year":"2005","journal-title":"Int. J. Oncol."},{"issue":"10","key":"10.1016\/j.cbi.2008.10.008_bib25","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1046\/j.1538-7836.2003.00446.x","article-title":"Aspirin and salicylate inhibit colon cancer medium- and VEGF-induced endothelial tube formation: correlation with suppression of cyclooxygenase-2 expression","volume":"1","author":"Shtivelband","year":"2003","journal-title":"J. Thromb. Haemost."},{"issue":"7","key":"10.1016\/j.cbi.2008.10.008_bib26","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1093\/rheumatology\/keh627","article-title":"Pharmacokinetic-pharmacodynamic correlations and biomarkers in the development of COX-2 inhibitors","volume":"44","author":"Huntjens","year":"2005","journal-title":"Rheumatology (Oxford, England)"},{"issue":"3","key":"10.1016\/j.cbi.2008.10.008_bib27","first-page":"275","article-title":"A dose-finding study of aspirin for chemoprevention utilizing rectal mucosal prostaglandin E(2) levels as a biomarker","volume":"11","author":"Sample","year":"2002","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"10.1016\/j.cbi.2008.10.008_bib28","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S0952-3278(97)90584-6","article-title":"Expression of recombinant human cyclooxygenase isoenzymes in transfected COS-7 cells in vitro and inhibition by tenoxicam, indomethacin, and aspirin","volume":"56","author":"Lora","year":"1997","journal-title":"Prostagalndins Leukot. Essent. Fatty Acids"},{"key":"10.1016\/j.cbi.2008.10.008_bib29","series-title":"AACR Annual Meeting","article-title":"Chemopreventive effects of Iressa, aspirin, and resveratrol against OH-BBN induced urinary bladder tumors","author":"Grubbs","year":"2007"}],"container-title":["Chemico-Biological Interactions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009279708005462?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009279708005462?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T13:19:43Z","timestamp":1757855983000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009279708005462"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,5]]},"references-count":29,"journal-issue":{"issue":"2-3","published-print":{"date-parts":[[2009,5]]}},"alternative-id":["S0009279708005462"],"URL":"https:\/\/doi.org\/10.1016\/j.cbi.2008.10.008","relation":{},"ISSN":["0009-2797"],"issn-type":[{"value":"0009-2797","type":"print"}],"subject":[],"published":{"date-parts":[[2009,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of pharmacokinetic and pharmacodynamic profiles of aspirin following oral gavage and diet dosing in rats","name":"articletitle","label":"Article Title"},{"value":"Chemico-Biological Interactions","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cbi.2008.10.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 Elsevier Ireland Ltd. Published by Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}